KR910001068A - 항생제 - Google Patents

항생제 Download PDF

Info

Publication number
KR910001068A
KR910001068A KR1019900009708A KR900009708A KR910001068A KR 910001068 A KR910001068 A KR 910001068A KR 1019900009708 A KR1019900009708 A KR 1019900009708A KR 900009708 A KR900009708 A KR 900009708A KR 910001068 A KR910001068 A KR 910001068A
Authority
KR
South Korea
Prior art keywords
compound
nutrient medium
mannitol
composition
useful
Prior art date
Application number
KR1019900009708A
Other languages
English (en)
Other versions
KR0145693B1 (ko
Inventor
이.슈와츠 로버트
에프. 하이트 레이몬드
엠. 리이쉬 제롤드
디. 헨센 오토
조슈아 헨리
엠. 슈마츠 데니스
에스. 트칵쯔 쟌
카플란 루이스
에스. 소사 마가렛
엠. 파운토우라키스 지미
에이. 지아코베 로비트
에스. 마수레카르 프라카쉬
Original Assignee
제임스 에프. 너턴
머크 앤드 캄파니 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/492,026 external-priority patent/US5021341A/en
Application filed by 제임스 에프. 너턴, 머크 앤드 캄파니 인코포레이티드 filed Critical 제임스 에프. 너턴
Publication of KR910001068A publication Critical patent/KR910001068A/ko
Application granted granted Critical
Publication of KR0145693B1 publication Critical patent/KR0145693B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

내용 없음.

Description

항생제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 화합물(I) 의 정제 샘플의1H NMR을 나타낸다.

Claims (16)

  1. 구조식(I)의 화합물.
  2. 제1항에 있어서, 1-[4,5-디하이드록시-N2-(10,12-디메틸-1-옥소테트라데실)-오르니틴]-5-(3-하이드록시-글루타민)-6-[3-하이드록시-프롤린]에키노칸딘 B로 명명된 화합물.
  3. 약제학적으로 허용되는 담체와의 혼합물로 제1항의 화합물을 함유함을 특징으로 하는 조성물.
  4. 제3항에 있어서, 진균생육을 억제시키는데 유용한 조성물.
  5. 제3항에 있어서, 뉴모시스티스 카리니(Pneumocystis Carimii)치료에 유용한 조성물.
  6. 진균 생육이 억제되어야 하는 영역에 항진균 유효량의 제1항의 화합물을 적용시킴을 특징으로하여, 진균생육을 억제하는 방법.
  7. 뉴모시스티스 카리니 감염증 치료 유효량의 제1항의 화합물을 포유동물에게 투여함을 특징으로 하여, 포유동물에서의 뉴모시스티스 카리니 감염증을 치료 또는 예방하는 방법.
  8. 비천연 아미노 산이 주요 질소원으로서 존재하는 영양 배지 중에서 잘레리온 이르보리콜리(Zalerion Orb-oricola)를 배양함을 특징으로 하여, 제1항의 화합물을 생산하는 방법.
  9. 주요 탄소원으로서 만니톨이 강화된 영양배지중에서 잘레리온 아르보리콜라 ATCC 20868을 배양함을 특징으로 하여, 제1항의 화합물을 생산하는 방법.
  10. (1) 만니톨을 포함하는 탄소원, (2) 우유 단백질 가수분해물을 포함하는 질소원, 및 (3) 글리산 또는 무기인산염을 포함하는 완충물질을 함유하는 수성 영양 배지에서 잘레리온 아르보리콜라를 배양함을 특징으로 하여, 증가된 수율로 제1항의 화합물을 생산하는 방법.
  11. 제10항에 있어서, 사용하는 영양 배지가 또한 미량 원소 및 락트산을 함유하는 방법.
  12. 제11항에 있어서, 사용하는 영양 배지가 또한 대두, 피넛 또는 해바라기 오일중에서 선택된 식물성 오일을 함유하는 방법.
  13. 수성 배지 리터 당, D-만니톨 20 내지 100g :KH2PO40.5내지 3g : 글리신 1 내지 4g : 펩톤화 우유 2 내지 20g : 락트산 0 내지 3g : 미량 원소 용액 0 내지 15㎖ : 및 식물성 오일 0 내지 20g을 함유함을 특징으로 하는, 제1항의 화합물을 증가된 수율로 생산하는데 유용한 영양 배지.
  14. 만니톨을 4중량%이상의 양으로 함유하는 영양배지 중에서 잘레리온 아르보리콜라를 배양하고 PH를 약 5.5에서 유지시킴을 특징으로 하여, 화합물(I)의 생산율을 증가시키는 방법.
  15. 만니톨을 약 4중량%이상 및 PH를 약 5.5에서 유지시키기 위한 완충물질을 함유하는 동화성 탄소, 동화성 질소 및 무기염의 영양 배지임을 특징으로 하는, 제1항중 구조식(I)화합물의 생산율을 증가시키는데 유용한 영양배지.
  16. 동화성 탄소원, 질소원 및 무기염원을 함유하는 영양 배지중에 호기적 조건하에서 구조식(I)의 화합물이 충분한 양 생산될 때까지 MF5404 잘레리온 아르보리콜라 ATCC20957을 배양시킨 후 배지로부터 생성물을 분리 시킴을 특징으로 하여, 주산물로서 제1항의 구조식(I)화합물을 생산하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900009708A 1989-06-30 1990-06-29 항생제 KR0145693B1 (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US37441689A 1989-06-30 1989-06-30
US?374,416? 1989-06-30
US374,416 1989-06-30
US49202590A 1990-03-12 1990-03-12
US49202490A 1990-03-12 1990-03-12
US07/492,026 US5021341A (en) 1990-03-12 1990-03-12 Antibiotic agent produced by the cultivation of Zalerion microorganism in the presence of mannitol
US?492,026? 1990-03-12
US492,024 1990-03-12
US?492,025? 1990-03-12
US?492,024? 1990-03-12
US492,026 1990-03-12
US492,025 1990-03-12

Publications (2)

Publication Number Publication Date
KR910001068A true KR910001068A (ko) 1991-01-30
KR0145693B1 KR0145693B1 (ko) 1998-08-01

Family

ID=27503114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900009708A KR0145693B1 (ko) 1989-06-30 1990-06-29 항생제

Country Status (16)

Country Link
EP (1) EP0405997B1 (ko)
JP (1) JPH0764873B2 (ko)
KR (1) KR0145693B1 (ko)
AT (1) ATE109160T1 (ko)
AU (1) AU639698B2 (ko)
CA (1) CA2020062C (ko)
CY (1) CY1962A (ko)
DE (1) DE69011006T2 (ko)
DK (1) DK0405997T3 (ko)
ES (1) ES2057413T3 (ko)
FI (1) FI93647C (ko)
HK (1) HK209496A (ko)
IL (1) IL94862A (ko)
NO (1) NO178343C (ko)
NZ (1) NZ234225A (ko)
PT (1) PT94555B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2037957A1 (en) * 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
US5310873A (en) * 1990-03-12 1994-05-10 Merck & Co., Inc. Cyclohexapeptide compound
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
CA2093429A1 (en) * 1990-10-09 1992-04-10 Shieh-Shung T. Chen Process for biophosphorylating organic compounds
US5219985A (en) * 1990-10-31 1993-06-15 Merck & Co., Inc. Antifungal agent
US5229363A (en) * 1991-02-19 1993-07-20 Merck & Co., Inc. Cyclic hexapeptide compounds
US5369093A (en) * 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5336756A (en) * 1991-05-01 1994-08-09 Merck & Co., Inc. Process for crystalline cyclic lipopeptides
US6030944A (en) * 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5348940A (en) * 1991-10-01 1994-09-20 Merck & Co., Inc. Cyclohexapeptidyl hydroxypropionitrile compounds
US5914313A (en) * 1991-10-17 1999-06-22 Merck & Co., Inc. 1- 4-hydroxy-5-aminoethyloxy-N2 -(10,12-dimethyl-1-oxotetradecyl)ornithine!-5-(3-hydroxyglutamine)-6-(3-hydroxyproline)echinocandin B, other aminoalkyl derivatives and salts thereof
DE69212267T2 (de) * 1991-10-17 1997-01-30 Merck & Co Inc Echinocandin-B-Derivat
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
WO1994025045A1 (en) * 1993-05-04 1994-11-10 Merck & Co., Inc. Cyclohexapeptidyl aminoalkyl ethers
WO2005004852A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
CN102618604B (zh) * 2011-01-31 2014-09-03 上海天伟生物制药有限公司 一种环脂肽化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1182812A (en) * 1979-12-13 1985-02-19 Bernard J. Abbott Process for the preparation of derivatives of cyclic peptide nuclei
CA1183127A (en) * 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
WO1982000587A1 (en) * 1980-08-15 1982-03-04 Tscherter H New metabolites,processes for their production and their use
DE3886001T2 (de) * 1987-10-07 1994-05-26 Merck & Co Inc Fungizides Fermentationsprodukt.

Also Published As

Publication number Publication date
CA2020062C (en) 1997-01-14
HK209496A (en) 1996-11-29
KR0145693B1 (ko) 1998-08-01
NZ234225A (en) 1993-09-27
EP0405997A1 (en) 1991-01-02
JPH0764873B2 (ja) 1995-07-12
IL94862A (en) 1994-10-07
PT94555B (pt) 1997-02-28
AU639698B2 (en) 1993-08-05
IL94862A0 (en) 1991-04-15
AU5797390A (en) 1991-01-03
CY1962A (en) 1997-07-04
JPH03163096A (ja) 1991-07-15
DE69011006T2 (de) 1995-01-26
NO902921L (no) 1991-01-02
DK0405997T3 (da) 1994-10-31
ATE109160T1 (de) 1994-08-15
FI93647C (fi) 1995-05-10
EP0405997B1 (en) 1994-07-27
NO178343B (no) 1995-11-27
ES2057413T3 (es) 1994-10-16
FI93647B (fi) 1995-01-31
PT94555A (pt) 1991-05-22
FI903280A0 (fi) 1990-06-28
DE69011006D1 (de) 1994-09-01
NO178343C (no) 1996-03-06
NO902921D0 (no) 1990-06-29
CA2020062A1 (en) 1990-12-31

Similar Documents

Publication Publication Date Title
KR910001068A (ko) 항생제
Bajwa et al. The biology of mycorrhiza in the ricaceae: ix. peptides as nitrogen sources for the ericoid endophyte and for mycorrhizal and non‐mycorrhizal plants
Higuchi et al. Studies on the nutrition and physiology of Pasteurella pestis: III. Effects of calcium ions on the growth of virulent and avirulent strains of Pasteurella pestis
Katz et al. The role of nutrition in the synthesis of actinomycin
KR880004097A (ko) 글리코펩티드 항생물질
Klumpp et al. Characterization of a Ca2+‐dependent guanylate cyclase in the excitable ciliary membrane from Paramecium
MR et al. Crystalline bacterial penicillinase.
EP0366060A1 (de) Glykosidase-Inhibitor Salbostatin, Verfahren zu seiner Herstellung und seine Verwendung
KR940005656B1 (ko) 테이코플라닌 a₂복합체의 단일 주 성분들의 비율을 선택적으로 증가시키는 방법
Duthie et al. Purification of free staphylococcal coagulase
CZ138194A3 (en) Lipopeptides produced by bacteria of actinoplanes strain exhibiting pharmacological activity, processes of their preparation and their use
KUNZE et al. Isolation and identification of althiomycin from Cystobacter fuscus (Myxobacterales)
Laki The action of thrombin on fibrinogen
US3580810A (en) Fermentative production of l-threonine
CA1198695A (en) Antibiotic compound
KR900009992A (ko) Ab-021 항생제 및 그의 제조방법
JPH02167069A (ja) スタフィロコッカス・エピデルミディスおよび医薬組成物
Yusef The requirements of some Hymenomycetes for essential metabolites
KR880001821A (ko) 글리코펩티드 항생물질
Wolin et al. An improved synthetic medium for the rapid production of chlamydospores by Candida albicans
AGRAWAL et al. Secretion of Acid Phosphatase by x4xenic Entamoeba histolytica NIH‐200 and Properties of the Extracellular Enzyme
US3875005A (en) Thrombolytic and fibrinolytic enzyme from streptomyces
Cutts et al. Nutrition of a strain of brewer's yeast requiring p-aminobenzoic acid
DE1960524C3 (de) Fermentatives Verfahren zur Herstellung von L-3,4-Dihydroxyphenylalanin
Nimi et al. Effect of arginine on gramicidin S biosynthesis by Bacillus brevis

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120427

Year of fee payment: 15

EXPY Expiration of term